Incyte Corporation (INCY)
NASDAQ: INCY · Real-Time Price · USD
98.22
0.00 (0.00%)
At close: Jun 18, 2026, 4:00 PM EDT
99.94
+1.72 (1.75%)
Pre-market: Jun 22, 2026, 9:00 AM EDT
Incyte Revenue
Incyte had revenue of $1.27B in the quarter ending March 31, 2026, with 20.87% growth. This brings the company's revenue in the last twelve months to $5.36B, up 21.48% year-over-year. In the year 2025, Incyte had annual revenue of $5.14B with 21.22% growth.
Revenue (ttm)
$5.36B
Revenue Growth
+21.48%
P/S Ratio
3.66
Revenue / Employee
$1,885,028
Employees
2,844
Market Cap
19.62B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 5.14B | 900.02M | 21.22% |
| Dec 31, 2024 | 4.24B | 545.57M | 14.76% |
| Dec 31, 2023 | 3.70B | 301.01M | 8.87% |
| Dec 31, 2022 | 3.39B | 408.37M | 13.67% |
| Dec 31, 2021 | 2.99B | 319.57M | 11.98% |
| Dec 31, 2020 | 2.67B | 507.94M | 23.53% |
| Dec 31, 2019 | 2.16B | 276.88M | 14.71% |
| Dec 31, 2018 | 1.88B | 345.66M | 22.50% |
| Dec 31, 2017 | 1.54B | 430.50M | 38.93% |
| Dec 31, 2016 | 1.11B | 351.97M | 46.70% |
| Dec 31, 2015 | 753.75M | 242.26M | 47.36% |
| Dec 31, 2014 | 511.50M | 508.45M | 16,696.71% |
| Dec 31, 2013 | 3.05M | -294.01M | -98.97% |
| Dec 31, 2012 | 297.06M | 202.60M | 214.50% |
| Dec 31, 2011 | 94.46M | -75.42M | -44.40% |
| Dec 31, 2010 | 169.88M | 160.61M | 1,733.55% |
| Dec 31, 2009 | 9.27M | 5.35M | 136.41% |
| Dec 31, 2008 | 3.92M | -30.52M | -88.62% |
| Dec 31, 2007 | 34.44M | 6.80M | 24.59% |
| Dec 31, 2006 | 27.64M | 19.80M | 252.32% |
| Dec 31, 2005 | 7.85M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BeOne Medicines AG | 5.70B |
| Jazz Pharmaceuticals | 4.44B |
| Genmab | 3.90B |
| BioNTech SE | 3.23B |
| Exelixis | 2.38B |
| Moderna | 2.23B |
| Ascendis Pharma | 998.25M |
| Insmed | 819.56M |
INCY News
- 4 hours ago - Incyte upgraded to Market Perform from Underperform at BMO Capital - TheFly
- 3 days ago - Incyte Japan announces approval of Minjuvi combination for DLBCL - TheFly
- 3 days ago - Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) - Business Wire
- 7 days ago - Incyte, Mirum announces Phase 2 results from Cohort 1 of Progress study - TheFly
- 7 days ago - Incyte announces clinical data from two Phase 2 studies of INCA033989 - TheFly
- 7 days ago - Incyte announces results from Phase 3 frontMIND trial of tafasitamab - TheFly
- 7 days ago - Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva - Business Wire
- 8 days ago - Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia - Business Wire